An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs GSK 1360707 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Pharmacokinetics
- 25 Jun 2011 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 09 Jul 2010 New trial record